The GOLGA7 Knockout A-549 Polyclonal Cells are a heterogeneous CRISPR/Cas9-edited population of A-549 cells with targeted disruption of the GOLGA7 gene. This polyclonal format provides a diverse loss-of-function background while avoiding clonal selection biases, suitable for robust population-level functional studies. The cells maintain the parental lung adenocarcinoma epithelial characteristics, facilitating consistent genetic manipulation analyses.
The A-549 cell line originates from the lung adenocarcinoma of a 58-year-old Caucasian male and is a well-established model of human alveolar type II pulmonary epithelium. These cells are extensively used in cancer biology, drug response, and respiratory research due to their adherent growth, stable karyotype, and expression of hallmark epithelial markers. Their reliability and extensive literature support make them a preferred host for interrogating gene function in lung adenocarcinoma contexts.
GOLGA7 encodes a golgin localized to the cytoplasmic face of the Golgi apparatus, where it serves as a tethering factor for COPI vesicles during retrograde intra-Golgi transport. It interacts with GM130, GOLGA5 (golgin-84), and GORASP1 (GRASP65) and is regulated by ARF1 GTPase and cell cycle signals. This tethering facilitates SNARE-mediated fusion via STX5 and BET1, maintaining Golgi stack integrity and secretory trafficking. Downstream, GOLGA7 is required for proper mitotic spindle organization, linking Golgi fragmentation to mitotic progression. Knockout of GOLGA7 disrupts Golgi ribbon formation, impairs protein secretion, and can lead to mitotic defects.
In A-549 lung adenocarcinoma cells, GOLGA7 loss disrupts the Golgi architecture, which is integral to oncogenic processes such as growth factor secretion, cell surface receptor presentation, and extracellular matrix remodeling. Impaired secretory flux may alter cell migration and invasion capabilities, while defective mitotic Golgi fragmentation can compromise chromosome segregation. Consequently, this model is highly relevant for dissecting the role of Golgi-dependent trafficking in tumor progression and drug resistance.
These polyclonal knockout cells enable detailed mechanistic studies using immunofluorescence (GM130, giantin) to assess Golgi morphology, Western blotting to confirm GOLGA7 ablation, and Gaussia luciferase secretion assays to quantify trafficking efficiency. Functional assays such as Transwell migration/invasion and MTT drug sensitivity tests can evaluate phenotypic outcomes, while flow cytometry provides cell cycle and apoptosis data. For more information, contact Ascent Research.
